NCT01111448终止2 期
Treatment of MDS Patients With Single Agent Temsirolimus - a Pilot Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 20
- 试验地点
- 7
- 主要终点
- Overall hematological response rate using modified IWG criteria (combination of CR, PR, marrow-CR and SD with HI).
研究概览
简要总结
The goal of this Pilot-study is to evaluate the response of unselected MDS patients to temsirolimus a drug approved for the treatment of renal cell cancer. It is planned to give temsirolimus at a weekly dose of 25 mg as intravenous infusion for a maximum duration of 12 months. Regular bone marrow biopsies are planned for controlling MDS response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >18 years at the time of signing the informed consent form;
- •Patients able to understand the consequences of participating in this trial and not having any disorders or other circumstances (i.e. being in ward or imprisoned) which keeps them from giving written informed consent;
- •cytologically or histologically established diagnosis of de novo or therapy-related MDS according to the FAB-classification, either previously treated or untreated, presenting with:
- •Group I (low-risk): Low- or INT-1 risk features according to IPSS and requiring at least 4 units of red blood cells within the last 8 weeks prior to screening visit or presenting with neutropenia (<1 Gpt/l neutrophils) or
- •Group II (high-risk): INT-2 or HIGH-risk IPSS refractory or intolerant to 5-Azacytidine.
- •CMML patients of dysplastic phenotype (WBC < 13 Gpt/l) may be included in both arms according to IPSS. CMML patients showing proliferative phenotype (WBC >=13 Gpt/l) will be included in the high risk arm;
- •not eligible for an immediate allogeneic HSCT or conventional chemotherapy;
- •all previous MDS specific therapies (except supportive approaches like transfusions or antibiotics) must have been discontinued at least 4 weeks prior to study enrollment;
- •ECOG performance status of <= 3 at study entry;
- •laboratory test results within these ranges:
- •Serum creatinine <= 177 µmo/l (<= 2.0 mg/dL);
- •total bilirubin <= 3 x ULN;
- •AST (SGOT) and ALT (SGPT) <= 3 x ULN;
- •total fasting cholesterol <= 9.1 mmol/l (350 mg/dl);
- •fasting triglyceride level <= 4.5 mmol/l (400 mg/dl);
- •platelets > 25 Gpt/l without transfusion support in patients with LOW- and INT-1 Risk according to IPSS;
- •signed informed consent.
排除标准
- •For Patients with LOW- or INT1-Risk according to IPSS: Thrombocytopenia below 25 Gpt/l (INT2- and HIGH-IPSS patients may be included irrespective of platelet count);
- •known hypersensitivity to temsirolimus, sirolimus or any components of the infusion solution (dl-alpha-tocopherol, propylene glycol, anhydrous citric acid, polysorbate 80, polyethylene glycol 400, dehydrated alcohol);
- •known hypersensitivity to macrolid antibiotics (because of structural similarities between this class of antibiotics and study medication);
- •any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study;
- •known positive for HIV or any other uncontrolled infection;
- •presence of any other malignancy being not in complete remission for at least 3 years (previous chemotherapy for other malignancies is not an exclusion criteria);
- •necessity of therapeutic anticoagulation (excluding low dose ASS);
- •participation in an other clinical trial within the last 4 weeks;
- •pregnant or breast feeding females (lactating females must agree not to breast feed while on study);
- •females of childbearing potential (FCBP) except those fulfilling at least one of the following criteria:
- •post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with serum FSH > 40 U/ml);
- •post-surgery (6 weeks after bilateral ovarectomy with or without hysterectomy);regular and correct use of contraceptives with a PEARL Index of < 1% (e.g. implants, depot formulations of hormones, oral contraceptives, intra uterine device - IUD);
- •sexual abstinence;
- •partner, who had vasectomy (confirmed by two negative analyses of semen);
- •male patients, who do not agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 3 months following discontinuation from the study even if he has undergone a successful vasectomy;
- •patients with a history of chronic drug abuse or another illness which does not allow the patient to assess the nature and/or possible consequences of the study;
- •patients who are not likely to follow the trial protocol (lack of willingness to cooperate).
研究组 & 干预措施
Temsirolimus
Experimental
25 mg/day 1; 8; 15; 22 of each 28-day cycle
干预措施: Temsirolimus (Drug)
结局指标
主要结局
Overall hematological response rate using modified IWG criteria (combination of CR, PR, marrow-CR and SD with HI).
时间窗: at 4 months
次要结局
- Toxicity as measured by NCI CTCAE v3.0(4 and 12 months)
- Overall survival(1 year)
- Rate of leukemic progression(1 year)
- Progression-free-survival(1 year)
- Overall hematological response rate using modified IWG-criteria(1 year)
- Quality of life as measured by EORTC-QLQ30(4 months, 12 months)
研究者
研究点 (7)
Loading locations...
相似试验
进行中（未招募）
不适用
Treatment of MDS patients with single agent temsirolimus – a pilot studyMyelodysplastic Syndromes (MDS)(20 IPSS LOW+INT-1 and 20 IPSS INT-2+HIGH or proliferating CMML)MedDRA version: 14.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014768-21-DEDresden Technical University
招募中
2 期
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's TypeAgitationNCT06052254Teikoku Pharma USA, Inc.150
已完成
不适用
Clinical Evaluation of MDT-2111 in Subjects With Symptomatic Severe Aortic StenosisAortic Valve StenosisNCT01437098Medtronic Cardiovascular55
已完成
2 期
Clinical Investigation of the MiStent Drug Eluting Stent (DES) in Coronary Artery DiseaseCoronary Artery DiseaseNCT01294748Micell Technologies184
终止
3 期
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMAMDSRefractory Anemia With Excess BlastsRAEBMyelodysplastic SyndromeNCT02562443Traws Pharma, Inc.372